Purpose: The prognostic factors of chondrosarcoma remain uncertain as only a few large studies with long-term follow-up have been reported. The aim of this study was to analyze oncological outcomes and prognostic factors.
Materials And Methods: A retrospective review of oncological outcomes and prognostic factors was performed on 125 consecutive chondrosarcoma patients who underwent surgery at our institution.
Results: Overall survival was 91.6%±2.5%, 84.1%±3.8%, and 84.1%±3.8% at 5, 10, and 15 years respectively. Among the histological types, dedifferentiated type showed the worst survival (p < 0.001). As for conventional type chondrosarcoma, histologic grade and anatomical location predicted outcome, with high-grade with axial location having the worst outcome (p < 0.001). In contrast, low-grade chondrosarcoma of appendicular skeleton could be treated safely by intralesional curettage.
Conclusion: Histological type was significantly associated with the outcome of chondrosarcoma. For the conventional type, histologic grade and anatomical location predicted outcome, with high-grade with axial location having the worst outcome.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4614192 | PMC |
| http://dx.doi.org/10.4143/crt.2014.135 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Frequency and treatment outcomes of chest wall masses: a 10-year report.
Kardiochir Torakochirurgia Pol
December 2024
Endoscopic and Minimally Invasive Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Introduction: Chest wall tumors, though rare, represent a significant subset of thoracic neoplasms, accounting for approximately 5% of thoracic and 2% of overall body neoplasms. Their management has historically posed challenges for surgeons, often leading to misdiagnosis, incomplete resection, and high complication rates. An individualized surgical approach, tailored to the specific characteristics of the disease, is crucial for optimizing outcomes.
View Article and Find Full Text PDFChondrosarcoma proximal tibia secondary to chondromyxoid fibroma: A rare case report.
Int J Surg Case Rep
January 2025
Department of Orthopaedics, All India Institute of Medical Sciences (AIIMS), Marudhar Industrial Area, 2nd phase, M.I.A. 1st phase, Basni, Jodhpur, Rajasthan 342005, India.
Introduction: Benign cartilage tumours with malignant transformation are reported very few. Aiming to report a secondary chondrosarcoma in proximal tibia after chondromyxoid fibroma: a rare entity with limited experience of management.
Case Presentation: we present a challenging case of secondary chondrosarcoma of proximal tibia in surgically managed chondromyxoid fibroma.
The size of local recurrence influences outcomes in chondrosarcoma: Significant impact observed in grade 2 tumours.
J Clin Orthop Trauma
January 2025
Royal Orthopaedic Hospital, Birmingham and Aston University Medical School, Aston University, Birmingham, B4 7ET, UK.
Background: Chondrosarcoma is the second most common bone malignancy. Chondrosarcoma is considered a surgical disease, and the role of surgical margin is important since local recurrence is known to decrease survival. The aim of this study was to investigate the timing of local recurrence and the size of local recurrence in post local recurrence survival in chondrosarcoma.
View Article and Find Full Text PDFAggressive Subtypes of Laryngeal Chondrosarcoma and their Clinical Behavior: A Systematic Review.
Oncol Ther
January 2025
Coordinator of the International Head and Neck Scientific Group, Padua, Italy.
Introduction: Laryngeal chondrosarcoma (CS) is a rare indolent malignant tumor. High-grade (G3), dedifferentiated (DD), and myxoid (MY) CSs are considered more aggressive subtypes due to their metastatic potential and relatively poor outcomes. The aim of this systematic review is to evaluate treatment modalities and survival outcomes in patients affected by these rarer CS subtypes.
View Article and Find Full Text PDFTranscriptomic data integration and analysis revealing potential mechanisms of doxorubicin resistance in chondrosarcoma cells.
Biochem Pharmacol
December 2024
Department of Medical Laboratory Science and Biotechnology, Asia University, Taichung 41354, Taiwan; Graduate Institute of Biomedical Science, China Medical University, Taichung 40402, Taiwan; Department of Pharmacology, School of Medicine, China Medical University, Taichung 40402, Taiwan; Chinese Medicine Research Center, China Medical University, Taichung 40402, Taiwan. Electronic address:
Chondrosarcoma is a type of bone cancer that originates from cartilage cells. In clinical practice, surgical resection is the primary treatment for chondrosarcoma, but chemotherapy becomes essential for patients with metastasis or tumors in surgically inaccessible sites. However, drug resistance often leads to treatment failure.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!